Baclofen as relapse prevention in the treatment of Gamma-hydroxybutyrate (GHB) dependence: an open label study.

ijmegen Institute for Scientist-Practitioners in Addiction (NISPA)/ Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results0 sites100 target enrollmentTBD

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Not specified
Sponsor: ijmegen Institute for Scientist-Practitioners in Addiction (NISPA)/ Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results
Enrollment: 100
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

ijmegen Institute for Scientist-Practitioners in Addiction (NISPA)/ Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results

Eligibility Criteria

Inclusion Criteria

•GHB dependence is the primary diagnosis, according to the DSM\-IV criteria. Patients are between 18\-65 years old and should be able to read and speak Dutch sufficiently

Exclusion Criteria

•Patients with any current physical or psychiatric safety concerns are excluded.
•Exclusion criteria are:
•\- Presence of a somatic safety concerns. These include liver cirrhosis and impaired renal function (as indicated by aspartate aminotransferase (AST), alanine transaminase (ALT), or gamma\-glutamyl transferase (GGT) level \>3 times the upper limit of normal (ULN); bilirubin \> ULN; serum creatinine \> ULN) , unstable hypertension, diabetes mellitus, and seizure disorder, including well controlled cases, currently taking anticonvulsants, insulin, or oral hypoglycemic and pregnancy.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Not Applicable

Baclofen as relapse prevention in the treatment of Gamma-hydroxybutyrate (GHB) dependence: an open label study.

NL-OMON39314Mental Health Care and Addiction Services (GGZ Nederland)/National program Scoring Results100

Completed

Not Applicable

Baclofen for maintenance treatment of opioid dependence: A randomised double-blind placebo-controlled clinical trial

ISRCTN32121581Roozbeh Addiction Department (Iran)40

Completed

Phase 3

Efficacy and safety of Baclofen GRS for treatment of alcohol dependence, a 12 week studyHealth Condition 1: F102- Alcohol dependenceHealth Condition 2: null- diagnosis of alcohol dependence

CTRI/2011/11/002154Sun Pharma Advanced Research Company Ltd195

Active, not recruiting

Not Applicable

A placebo controlled trial with Baclofen for the treatment of GERD patients with incomplete PPI responseGastroesophageal reflux disease

EUCTR2009-017351-96-BEZleuven

Active, not recruiting

Phase 1

Study investigating the effect of baclofen in patients with postprandial regurgitation or belchingRumination syndrome and supragastric belchingMedDRA version: 14.0Level: LLTClassification code 10039292Term: Rumination disorderSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.0Level: LLTClassification code 10004222Term: BelchingSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]

EUCTR2011-002745-35-BEZLeuven20